The Differential Contribution of the Innate Immune System to a Good Pathological Response in the Breast and Axillary Lymph Nodes Induced by Neoadjuvant Chemotherapy in Women with Large and Locally Advanced Breast Cancers
Table 11
Analyses of blood PMN neutrophils in women with LLABC and specific clinical and pathological parameters.
Groups
Pre-NAC median (range)(3)
value(4) (GPR versus PRR, PCR versus non-PCR)
Post-NAC median (range)(3)
value(4) (GPR versus PRR, PCR versus non-PCR)
Blood PMNs
Good pathological response (GPR, )
4.13 (2.15–11.30)
0.796
3.05 (1.40–6.75)
0.134
Poor pathological response (PPR, )
4.07 (1.80–10.10)
3.47 (0.03–8.73)
Pathological complete response (PCR, )
4.50 (2.15–11.30)
0.381
3.10 (1.40–6.75)
0.755
Nonpathological complete response (non-PCR, )
3.94 (1.80–10.10)
3.26 (0.03–8.73)
Nodal metastasis ()
3.94 (1.80–10.10)
0.634
3.11 (0.03–8.26)
0.337
No nodal metastasis ()
4.16 (2.15–11.30)
3.36 (1.54–8.73)
Nodal pCR ()
5.43 (2.84–10.10)
0.002
3.20 (1.40–8.26)
0.892
No nodal pCR ()
3.65 (1.80–9.17)
3.05 (0.03–6.37)
Recurrent disease(5) ()
4.02 (1.80–8.70)
0.612
3.19 (0.03–5.80)
0.878
No recurrent disease ()
4.10 (2.15–11.30)
3.23 (1.33–8.73)
Death(5) ()
3.87 (2.23–6.64)
0.276
3.00 (0.03–5.42)
0.360
Survive ()
4.11 (1.80–11.30)
3.23 (1.33–8.73)
LLABC: large and locally advanced breast cancers; NAC: neoadjuvant chemotherapy; (3)×109 cells/litre; (4)Mann–Whitney U test; (5)4-year follow-up; statistically significant.